Trial Profile
A randomised double-blinded study to assess the ability for intravitreal bevacizumab to increase the proportion of glaucoma patients with intraocular pressure at or below target following glaucoma drainage surgery.
Status:
Not yet recruiting
Phase of Trial:
Phase III/IV
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- 05 Jun 2014 New trial record